Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects

por Boyce, M, Warrington, S, Cortezi, B, Zöllner, S, Vauléon, S, Swinkels, D W, Summo, L, Schwoebel, F, Riecke, K
Publicado 2016

Randomized double-blind placebo-controlled PK/PD study on the effects of a single intravenous dose of the anti-hepcidin Spiegelmer NOX-H94 on serum iron during experimental human e...

por Van Eijk, L, Swinkels, DW, John, A, Schwoebel, F, Fliegert, F, Summo, L, Vauleon, S, Laarakkers, JM, Riecke, K, Pickkers, P
Publicado 2013

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

por Ludwig, H, Weisel, K, Petrucci, M T, Leleu, X, Cafro, A M, Garderet, L, Leitgeb, C, Foa, R, Greil, R, Yakoub-Agha, I, Zboralski, D, Vauléon, S, Dümmler, T, Beyer, D, Kruschinski, A, Riecke, K, Baumann, M, Engelhardt, M
Publicado 2017

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry

por Riecke, K., Müller, V., Neunhöffer, T., Park-Simon, T.-W., Weide, R., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lübbe, K., Hesse, T., Thill, M., Wuerstlein, R., Denkert, C., Decker, T., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Laakmann, E., Witzel, I.
Publicado 2023

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry

por Laakmann, E., Witzel, I., Neunhöffer, T., Park-Simon, T.-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lübbe, K., Hesse, T., Thill, M., Zahm, D.-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Müller, V.
Publicado 2022